Chimerix Inc (NASDAQ:CMRX) CEO Michael A. Sherman Buys 30,000 Shares

Chimerix Inc (NASDAQ:CMRX) CEO Michael A. Sherman acquired 30,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was acquired at an average price of $3.48 per share, with a total value of $104,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of CMRX stock traded down $0.02 during mid-day trading on Friday, reaching $3.51. The stock had a trading volume of 199,663 shares, compared to its average volume of 470,885. Chimerix Inc has a 12-month low of $1.74 and a 12-month high of $5.04. The stock has a market cap of $179.27 million, a P/E ratio of -2.45 and a beta of 1.08.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). Chimerix had a negative return on equity of 36.85% and a negative net margin of 757.77%. The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.00 million. Analysts forecast that Chimerix Inc will post -1.18 EPS for the current year.

Several research analysts have issued reports on CMRX shares. Cowen reiterated a “hold” rating and issued a $3.00 price objective on shares of Chimerix in a research report on Thursday, May 9th. Citigroup cut their price objective on Chimerix from $4.25 to $2.00 and set a “neutral” rating for the company in a research report on Wednesday, March 6th. ValuEngine cut Chimerix from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $4.75.

Hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP increased its position in shares of Chimerix by 52.9% in the fourth quarter. Two Sigma Investments LP now owns 308,732 shares of the biopharmaceutical company’s stock valued at $793,000 after buying an additional 106,750 shares in the last quarter. Rhumbline Advisers increased its position in shares of Chimerix by 45.7% in the fourth quarter. Rhumbline Advisers now owns 65,845 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 20,654 shares in the last quarter. Morgan Stanley increased its position in shares of Chimerix by 28.8% in the third quarter. Morgan Stanley now owns 2,041,150 shares of the biopharmaceutical company’s stock valued at $7,940,000 after buying an additional 456,290 shares in the last quarter. Deutsche Bank AG increased its position in shares of Chimerix by 27.7% in the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 55,950 shares in the last quarter. Finally, Pitcairn Co. purchased a new position in shares of Chimerix in the fourth quarter valued at $42,000. Institutional investors and hedge funds own 69.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://sundanceherald.com/2019/06/14/insider-buying-chimerix-inc-cmrx-ceo-buys-104400-00-in-stock.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply